Skip to main content

Table 3 Viral and bacterial infection status among pneumonia patients by comorbidity status

From: The impact of virus infections on pneumonia mortality is complex in adults: a prospective multicentre observational study

 

No comorbidities

Chronic respiratory disease

Other comorbiditiesa

P value†

Viruses

N = 574

N = 790

N = 1253

 

HRV

57 (9.9)

87 (11.0)

112 (8.9)

0.304

Inf A

21 (3.7)

29 (3.7)

51 (4.1)

0.866

RSV

12 (2.1)

37 (4.7)

52 (4.2)

0.037

PIV 3

12 (2.1)

11 (1.4)

26 (2.1)

0.492

HMPV

6 (1.1)

13 (1.7)

26 (2.1)

0.286

PIV 1

4 (0.7)

10 (1.3)

12 (1.0)

0.598

Inf B

5 (0.9)

5 (0.6)

14 (1.1)

0.596

PIV 2

3 (0.5)

4 (0.5)

7 (0.6)

1.000

HCoV (229E/OC43)

3 (0.5)

5 (0.6)

5 (0.4)

0.767

HAdV

2 (0.4)

1 (0.1)

3 (0.2)

0.764

HBoV

0 (0.0)

0 (0.0)

2 (0.2)

0.711

PIV 4

0 (0.0)

0 (0.0)

0 (0.0)

NA

Any viruses

118 (20.6)

196 (24.8)

291 (23.2)

0.183

≥2 viruses

7 (1.2)

6 (0.8)

18 (1.4)

0.386

Any bacterial pathogens

233 (40.6)

315 (39.9)

444 (35.4)

0.043

Viral-bacterial co-infection

54 (9.4)

88 (11.1)

104 (8.3)

0.101

Any viral and bacterial pathogens

297 (51.7)

423 (53.5)

631 (50.4)

0.373

  1. HRV human rhinovirus, InfA influenza A virus, RSV respiratory syncytial virus, PIV1–4 human parainfluenza virus type 1–4, HMPV human metapneumovirus, InfB influenza B virus, HCoV human coronavirus (229E/OC43), HAdV human adenovirus, HBoV human bocavirus
  2. † Chi-square tests or Fisher’s exact tests were performed to compare the three groups
  3. aOther comorbidities include diabetes mellitus, cerebrovascular disease, dementia, neuromuscular disease, cardiac failure, ischaemic heart disease, collagen disease, malignancy, renal disease, and liver disease